EYPT (EyePoint) Quality Rank


EYPT EyePoint Inc EYPT
34 GF Score
Price $14.72
GF Value $0.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

EyePoint Quality Rank Related Terms

EYPT
34GF Score
EyePoint Inc EYPT
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $14.72 is trading 1811.7% above its estimated GF Value™ of $0.77. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Quality Rank:
  • GF Value™: $0.77 vs. price of $14.72 (1811.7% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.72
Price
$0.77
GF Value